Innate Pharma (IPHA) Beginning Cash Balance (2020 - 2025)

Innate Pharma (IPHA) has reported Beginning Cash Balance for 6 consecutive years, with $75.6 million the latest figure, recorded in Q4 2025.

• Quarterly Beginning Cash Balance fell 5.96% year-over-year to $75.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $369.8 million (down 17.8% YoY) and the FY2025 annual result came in at $75.6 million, down 5.96% from the prior year.
• Beginning Cash Balance eased to $75.6 million in Q4 2025 per IPHA's latest filing, from $80.3 million in the prior quarter.
• Over the last five years, Beginning Cash Balance for IPHA reached as high as $155.7 million in Q4 2021 and fell as low as $75.6 million in Q4 2025.
• A 5-year average of $105.1 million and a median of $95.8 million in 2023 frame the typical range for Beginning Cash Balance.
• Annual changes were most pronounced in 2021 — Beginning Cash Balance slumped 32.58% — and 2025, when it decreased 5.96%.
• Year by year, Beginning Cash Balance stood at $155.7 million in 2021, then slipped by 24.15% to $118.1 million in 2022, then dropped by 18.82% to $95.8 million in 2023, then decreased by 16.17% to $80.3 million in 2024, then dropped by 5.96% to $75.6 million in 2025.
• According to Business Quant data, Beginning Cash Balance over the past three periods registered $75.6 million, $80.3 million, and $95.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.